氨磺必利、阿立哌唑与奥氮平治疗精神分裂症谱系障碍的实用随机对照试验
该实用、评定者盲法、半随机对照试验在挪威和奥地利4个中心纳入144例成人精神分裂症谱系障碍患者,随机分配至氨磺必利、阿立哌唑或奥氮平治疗52周。三组均观察到体重增加及血脂、催乳素升高,严重不良事件组间无显著差异。
要点
- 氨磺必利在52周时PANSS总分减分显著优于阿立哌唑和奥氮平。
- 三组均出现体重增加及血脂、催乳素升高,副作用差异总体较小。
- 严重不良事件组间无统计学显著差异,常见为再入院或延长住院。
核心结论
- 在成人精神分裂症谱系障碍患者中,氨磺必利降低PANSS总分的疗效优于阿立哌唑或奥氮平。
研究设计与样本
- 实用、评定者盲法、随机对照试验,在挪威3个和奥地利1个学术精神病学中心进行。
- 纳入144例18岁及以上、符合ICD-10精神分裂症谱系障碍(F20-29)且存在活跃精神病性症状的患者,按1:1:1随机分配至氨磺必利(44例)、阿立哌唑(48例)或奥氮平(52例)。
- 治疗分配对患者和 staff 开放,起始剂量、治疗变更和调整由主治医师决定,随访52周,由对治疗不知情的研究者进行8次评估。
主要发现
- 所有组均观察到体重增加及血清血脂和催乳素升高。
- 20例患者共登记26例严重不良事件(SAEs):氨磺必利组4例(9%),阿立哌唑组10例(21%),奥氮平组6例(12%),组间无统计学显著差异。
- 26例SAEs中17例(65%)发生在使用研究药物期间,其中13例SAEs为再入院或延长住院。
- 随访期间治疗停止后发生1例自杀死亡、1例不明原因死亡和1例危及生命的事故。
关键数值与推荐
- 主要结局为52周时阳性与阴性症状量表(PANSS)总分减分,主要分析在意向治疗人群中进行。
临床怎么用
- 对于成人精神分裂症谱系障碍患者,氨磺必利在改善PANSS总分方面可能优于阿立哌唑和奥氮平。
- 选择第一线抗精神病药时需权衡疗效差异与体重、血脂、催乳素等副作用。
局限性
- 治疗分配开放,起始剂量和调整由医师决定,可能引入实施偏倚。
- 样本量较小(144例),组间副作用差异可能不显著。
- 研究在挪威和奥地利进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Amisulpride, aripiprazole, and olanzapine are first-line atypical antipsychotics that have not previously been compared head-to-head in a pragmatic trial. We aimed to compare the efficacy and safety of these agents in a controlled trial. METHODS: This pragmatic, rater-blind, randomised controlled trial was done in three academic centres of psychiatry in Norway, and one in Austria. Eligible patients were aged 18 years or older, met ICD-10 criteria for schizophrenia-spectrum disorders (F20-29), and had symptoms of active psychosis. Eligible patients were randomly assigned to receive oral amisulpride, aripiprazole, or olanzapine. Treatment allocation was open to patients and staff, and starting dose, treatment changes, and adjustments were left to the discretion of the treating physician. Computer-generated randomisation lists for each study centre were prepared by independent statisticians. Patients were followed up for 52 weeks after random assignment, during which assessments were done 8 times by researchers masked to treatment. The primary outcome was reduction of the Positive And Negative Syndrome Scale (PANSS) total score at 52 weeks, and primary analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01446328. FINDINGS: Between Oct 20, 2011, and Dec 30, 2016, we assessed 359 patients for eligibility. 215 patients were excluded (107 did not meet inclusion criteria, 82 declined to participate, 26 other reasons). 144 patients (mean baseline PANSS total estimated score 78·4 [SD 1·4]) were randomly assigned 1:1:1 to receive amisulpride (44 patients), aripiprazole (48 patients) or olanzapine (52 patients). After 52 weeks, the patients allocated to amisulpride had a PANSS total score reduction of 32·7 points (SD 3·1) compared with 21·9 points reduction with aripiprazole (SD 3·9, p=0·027) and 23·3 points with olanzapine (2·9, p=0·025). We observed weight gain and increases of serum lipids and prolactin in all groups. 26 serious adverse events (SAEs) among 20 patients were registered (four [9%] of 44 patients allocated to amisulpride, ten [21%] of 48 patients allocated to aripiprazole, and six [12%] of 52 patients allocated to olanzapine), with no statistically significant differences between the study drugs. 17 (65%) of the 26 SAEs occurred during the use of the study drug, with readmission or protracted hospital admission accounting for 13 SAEs. One death by suicide, one unspecified death, and one life-threatening accident occurred during follow-up, after cessation of treatment. INTERPRETATION: Amisulpride was more efficacious than aripiprazole or olanzapine for reducing the PANSS total scores in adults with schizophrenia-spectrum disorders. Side-effect differences among the groups were generally small. This study supports the notion that clinically relevant efficacy differences exist between antipsychotic drugs. Future research should aim to compare first-line antipsychotics directly in pragmatic clinical trials that reflect everyday clinical practice. FUNDING: The Research Council of Norway, the Western Norway Regional Health Trust, and participating hospitals and universities.
引用
- Johnsen E, Kroken RA, Løberg EM, et al. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. Lancet Psychiatry. 2020. PMID: 33069317. doi:10.1016/S2215-0366(20)30341-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。